Hepatology
🇪🇺 EMAEMA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into the global hepatology drug market. Track R&D, regulatory approvals, and investment opportunities in liver disease therapeutics.
Showing 1–3 of 3 articles
Quick answer
NovaPharmaNews Hepatology hub for EMA covers 3 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Artiva Biotherapeutics' AlloNK Receives FDA Fast Track Designation for Refractory Rheumatoid Arthritis Treatment
Opella's Essentiale Shows 2.5x Greater Liver Fat Reduction in Breakthrough EXCEL Trial for Fatty Liver Disease
Brii Bio's Elebsiran Shows Durable Hepatitis B Control in APASL 2026 Cross-Study Analysis
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.